

FOR IMMEDIATE RELEASE:

**EBI ANNOUNCES EARLY RESULTS OF RADIATION PROTECTION
EXPERIMENTS**

McLean, Virginia, January 15, 2008 — Privately held Exponential Biotherapies, Inc. (“EBI”), a McLean, Virginia based drug discovery and development company, today announced early results of experiments exploring the use of its proprietary drug candidate in radiation protection.

In preliminary studies carried out at Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, in association with Montefiore Medical Center, Bronx, New York, by Alan A. Alfieri, Ph.D., Associate Professor, Department of Radiation Oncology, the company’s development stage drug was administered to animals that had received whole body radiation. Two sets of experiments were particularly noteworthy: In the first, animals that had received either intravenous or subcutaneous doses of the drug were found to be protected against organ damage and subsequent death. In the second, animals were protected when exposed to increasing doses of radiation, including radiation doses that were expected to kill 100% of the untreated animals.

“These experiments were particularly significant because the drug was administered hours after the animals were irradiated,” explained Zsolt Harsanyi, Ph.D., Chairman and CEO. “Most drugs being developed for radiation protection must be administered before or closely after exposure to radiation. While such drugs might be useful for first responders who would have to enter an area contaminated by radioactivity, those drugs would not be expected to help initial victims of radiation exposure.”

EBI’s drug is being formulated for rapid and easy injection to allow for field use in case of civilian or military radiobiological or nuclear threat.

About Exponential Biotherapies, Inc.

Exponential Biotherapies, Inc. (“EBI”) is a Virginia based drug discovery and development company with a growing pipeline of novel small molecule drugs to treat a wide range of severe inflammatory disorders such as septic shock, renal failure, radiation sickness and avian influenza. These compounds represent a new class of immune regulating therapeutic agents. The Company’s first candidate drug, EA-230, is about to enter Phase II clinical trials following a successful Phase I in which the drug was safely tolerated in both single and multi-dose studies as well as the LPS proof of concept, Phase I Expansion.

The Company has licensed a family of chemically synthesized biomolecules (the “Compounds”) that regulate the immune response. These biomolecules can either increase or decrease the activity of the immune system by affecting the activity of one or more of the components of the immune cascade.

About Albert Einstein College of Medicine

The Albert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation. It is the home to some 2,000 faculty members, 750 M.D. students, 350 Ph.D. students (including 125 in combined M.D./Ph.D. programs) and 380 postdoctoral investigators. Last year, Einstein received more than \$150 million in grant funding from the National Institutes of Health (NIH). In addition, the NIH funds major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Through its extensive affiliation network involving five hospital centers in the Bronx, Manhattan and Long Island - which includes Montefiore Medical Center, Einstein's officially designated University Hospital - the College runs the largest post-graduate medical training program in the United States, offering approximately 150 residency programs to more than 2,500 physicians in training. For more information, please visit www.aecom.yu.edu.

About Montefiore Medical Center

Montefiore Medical Center, the University Hospital and Academic Medical Center for the Albert Einstein College of Medicine, encompasses 125 years of innovative medical "firsts," pioneering clinical research, dedicated community service and ground-breaking social activism.

A full-service, integrated delivery system caring for patients in the New York metropolitan region and beyond, Montefiore is a 1,122-bed medical center that includes three hospitals: the Henry and Lucy Moses Division, the Jack D. Weiler Division and The Children's Hospital at Montefiore; a large home healthcare agency; the largest school health program in the US; a 21-site medical group practice integrated throughout the Bronx and Westchester; and a care management organization providing services to 179,000 health plan members.

The medical center is ranked by the prestigious Leapfrog Group among the top one percent of all U.S. hospitals based on its strategic investments in sophisticated and integrated healthcare technology.

Montefiore's distinguished centers of excellence include cardiology and cardiac surgery, cancer care, tissue and organ transplantation, children's health, women's health, surgery and the surgical subspecialties. Montefiore is a national leader in the treatment of diabetes, headaches, obesity, cough and sleep disorders, geriatrics and geriatric psychiatry, neurology and neurosurgery, adolescent and family medicine, HIV/AIDS and social and environmental medicine, among many other specialties. For more information, please visit www.montefiore.org and www.MonteKids.org.

Forward-looking statements

This press release contains forward looking statements, including statements related to our clinical trials and product candidates. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these or other risks and uncertainties, which include, without limitation, risks related to the progress, timing and

results of clinical trials (including our ability to initiate and complete subsequent clinical trials involving EA-230 or any other product candidate); risks that subsequent clinical trials may show EA-230 is not safe and/or effective; issues relating to the intellectual property upon which our drug candidates are dependent; difficulties or delays in obtaining regulatory approval or clearance which are necessary or advisable in the conduct of future clinical trials or are necessary for the commercialization of EA-230 or any of our other product candidates; manufacturing issues relating to EA-230 or any other drug candidate; our ability to obtain financial resources necessary to support our clinical trials, other operations and financial commitments; competitive issues; and other regulatory considerations which affect the business prospects of EBI. Given these and other uncertainties, you should not place undue reliance on these forward-looking statements.

Contact

Zsolt Harsanyi, Ph.D., Chairman and CEO

+1-703-883-3701